TRVI · Trevi Therapeutics, Inc.
$17.92
-0.03 (-0.17%)
At close · Aug 26
Market Cap
$2.55B
Shares
142.48M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$42.76M
+10.8%
FY2025
Diluted EPS
-$0.32
+31.9%
FY2025
Operating Cash Flow
-$42.09M
-10%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| $41.37M | $33.48M | $39.38M | $23.68M | $19.83M | $22.98M | $22.33M | $19.34M | $14.07M | |
| $18.19M | $15.85M | $12.15M | $10.24M | $10.07M | $9.49M | $10.16M | $7.31M | $4.34M | |
| — | $144K | $147K | $123K | $43K | — | — | — | — | |
| $59.56M | $49.33M | $51.52M | $33.92M | $29.91M | $32.48M | $32.49M | $26.65M | $18.41M | |
| -$59.56M | -$49.33M | -$51.52M | -$33.92M | -$29.91M | -$32.48M | -$32.49M | -$26.65M | -$18.41M | |
| — | $0 | $4000 | $391K | $1.16M | $1.2M | $456K | — | $174K | |
| $8.4M | $6.54M | $3.6M | $4.75M | — | — | — | — | — | |
| $8.38M | $6.51M | $3.58M | $4.83M | $719K | -$1.49M | -$287K | $577K | -$2.26M | |
| -$51.18M | -$42.82M | -$47.94M | -$29.1M | -$29.19M | -$33.96M | -$32.78M | -$26.07M | -$20.67M | |
| -$71K | -$64K | -$30K | -$32K | -$36K | -$21K | -$18K | -$18K | -$124K | |
| -$51.11M | -$42.76M | -$47.91M | -$29.07M | -$29.15M | -$33.94M | -$32.76M | -$26.05M | -$20.55M | |
| — | — | — | — | — | — | -$32.76M | -$26.75M | -$25.58M | |
| -$51.56M | -$42.67M | -$47.82M | -$28.97M | -$29.27M | -$33.94M | — | — | — | |
| USD/shares | — | -$0.32 | -$0.47 | -$0.29 | -$0.45 | -$1.49 | — | — | — |
| USD/shares | — | -$0.32 | -$0.47 | -$0.29 | -$0.45 | -$1.49 | — | — | — |
| shares | — | 134.75M | 101.97M | 99.03M | 64.54M | 22.84M | 18.06M | 11.74M | 437.61K |
| shares | — | 134.75M | 101.97M | 99.03M | 64.54M | 22.84M | 18.06M | 11.74M | 437.61K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.54×
EV/EBIT
—
Peer median 17.16×
P/E (TTM)
—
Peer median 18.05×
Peer medians compare against the 249 similar-size Biotechnology companies (of 534 listed).
Key facts
CIK
1563880
CUSIP
89532M101
13F (30d)
194 filings
193 filers
Visit website
Investor relations